Michael J. Fox Foundation Shifts Parkinson's Study to Precision Medicine

Event summary

  • The Michael J. Fox Foundation renames its 15-year-old Parkinson's Progression Markers Initiative (PPMI) to the Parkinson's Precision Medicine Initiative, reflecting a shift toward biology-driven research.
  • The study now includes over 4,200 in-clinic participants across 50 sites in 12 countries and over 47,000 online participants.
  • PPMI data has been downloaded more than 50 million times, accelerating discovery across the field.
  • The foundation has invested over $800 million in building one of the most comprehensive Parkinson's datasets in the world.

The big picture

The renaming of PPMI to the Parkinson's Precision Medicine Initiative marks a strategic pivot toward biology-driven research, aligning with broader industry trends in personalized medicine. With Parkinson's prevalence rising faster than projected and over 75 potential disease-modifying therapies in development, the shift underscores the urgency to move toward earlier and more targeted treatments. The foundation's extensive dataset and global participant base position it as a key player in advancing Parkinson's research.

What we're watching

Precision Medicine Adoption
How the shift to precision medicine will accelerate the development of targeted therapies for Parkinson's disease.
Data Utilization
Whether the extensive PPMI dataset will continue to drive breakthroughs in early detection and treatment.
Participant Engagement
The pace at which remote participation and digital health data contributions will expand the study's reach.

Related topics

Pharmaceuticals